July 30, 2024
CellCarta is bolstering its quantitative digital pathology capability with the global deployment of HALO AI from Indica Labs. Linking seamlessly with CellCarta’s advanced mIF and spatial analysis offerings, the AI-powered tool will support biopharma organizations to solve complex image analysis challenges in segmentation, classification, and phenotyping.
Sponsors harnessing this cutting-edge digital pathology platform will benefit from rapid, highly accurate, and cost-effective analysis of pathology images that enhance detection of target cells and exclusions of non-specific staining. This will be achieved via advanced deep learning networks that can be tuned for specific applications with HALO AI’s train-by-example interface.
CellCarta will utilize HALO AI for the development of automated scoring algorithms for analyzing clinical trial samples, following validation according to rigorous standard operating procedures. These algorithms will improve accuracy in segmenting complex tissue and/or cells, previously inaccessible without AI.
Dr. Ghislaine Lioux, Applications Scientist at Indica Labs, comments: “HALO AI takes quantitative image analysis to the next level. Its simple and intuitive workflow, powerful tissue segmentation, and exceptional cell classification capability combine to deliver unrivaled analysis proficiency that can help improve overall clinical trial success.”
CellCarta’s consolidated, GCP-compliant environment will also enable its clients to share their HALO AI algorithms quickly, conveniently, and securely. This will allow algorithms to be transferred and integrated into the quality system’s workflow for deployment in the clinical studies run at CellCarta.
Hosted in the secure and scalable Amazon Web Services (AWS) cloud environment, HALO AI will be accessible across all four of CellCarta’s global histopathology business units: Antwerp (BE), Jining (CH), Lake Forest (USA), and Naperville (USA).
Subject to comprehensive validation, according to CellCarta’s quality management system requirements, the platform will be seamlessly integrated into standard operational workflows and CellCarta’s LIMS ecosystem, providing a 21 CFR pt11 compliant solution.
Commenting on the launch, Elyne Backx, CellCarta’s Application Manager, said: “The AWS environment opens a world of possibility, allowing us to leverage central processing units and graphic processing units on demand to significantly reduce analysis turnaround times, while effectively managing imaging processing costs.”
Against the context of intense market competition, sponsors need specialist expertise, robust processes, and innovative technology to expedite timelines, safeguard continued funding and/or planned M&A activity, and increase first-mover advantage potential.
Where quantitative pathology image analysis is concerned, this means partnering with CROs capable of operating a controlled and auditable environment that delivers accuracy, speed, compliance, and cost-effectiveness.
Yannick Waumans, CellCarta’s Global Head of Digital Pathology, explains: “The use of AI in image analysis, and specifically deep learning, will significantly improve accuracy levels, leading to more precise measurement of target cells. Combined with appropriate training sets and our dedicated expert Digital Pathology Solutions team, we can develop robust algorithms that support our clients to overcome the most complex image analysis challenges efficiently, cost-effectively and in line with CellCarta’s excellent quality standards.”
A leading provider of specialized precision medicine laboratory services to the global biopharmaceutical industry, CellCarta offers a full range of testing services including:
Ready to take your clinical development forward with next-level digital pathology services? Discover more about powering histopathology with cutting-edge, AI-powered quantitative image analysis.
Posters
November 19, 2024
More info